Clinical Trials Browser

Phase 2 × Recruiting × Mycosis Fungoides × Clear all

Mycosis Fungoides

NCT03587844 2026-04-03

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Phase 2 Recruiting

58 enrolled

Lymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphomatoid Papulosis

NCT06854653 2026-03-31

A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

Phase 2 Recruiting

115 enrolled

DermatologicLymphoid

Lymphoma, Non-Hodgkin, Mycosis Fungoides, Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT05357794 2026-01-12

Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

Phase 2 Recruiting

30 enrolled

Lymphoid

Mycosis Fungoides

NCT06716658 2025-11-18

JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

Phase 2 Recruiting

48 enrolled

DermatologicLymphoidOther hematologic neoplasm

Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Leukemia, Large Granular Lymphocytic

NCT04930653 2025-10-14

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

Phase 2 Recruiting

34 enrolled

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT05680558 2025-09-23

Photopheresis in Early-stage Mycosis Fungoides

Phase 2 Recruiting

74 enrolled

DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT04256018 2025-07-02

Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome

Phase 2 Recruiting

30 enrolled

Lymphoid

Mycosis Fungoides, Sezary Syndrome

Clinical Trials

Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

Photopheresis in Early-stage Mycosis Fungoides

Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome